AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Primary Biliary Cirrhosis - Pipeline Insight, 2019 by Developmental Stage, Associated Indications, Route of Administration and Molecule Type - ResearchAndMarkets.com

February 27, 2019

DUBLIN--(BUSINESS WIRE)--Feb 27, 2019--The “Primary Biliary Cirrhosis - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Primary Biliary Cirrhosis - Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Primary Biliary Cirrhosis development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Scope of the Report

  • The report provides a snapshot of the pipeline development for the Primary Biliary Cirrhosis
  • The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Primary Biliary Cirrhosis
  • The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Primary Biliary Cirrhosis
  • The report also covers the dormant and discontinued pipeline projects related to Primary Biliary Cirrhosis

Reasons to Buy

  • Establish comprehensive understanding of the pipeline activity across this Primary Biliary Cirrhosis to formulate effective R&D strategies
  • Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
  • Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Primary Biliary Cirrhosis therapeutics
  • Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

Topics Covered

1. Report Introduction

2. Primary Biliary Cirrhosis Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Primary Biliary Cirrhosis

4. Comparative Analysis

5. Products in Clinical Stage

  • Product Description
  • Research and Development
  • Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment

  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

8. Inactive Products

  • Product Description
  • Research and Development
  • Product Development Activities

Companies Profiled

  • Albireo Pharma Inc.
  • Arena Pharmaceuticals Inc.
  • CymaBay Therapeutics Inc.
  • Eisai Co. Ltd.
  • Enanta Pharmaceuticals Inc.
  • Genfit S.A.
  • GenKyoTex S.A.
  • Gilead Sciences Inc.
  • GlaxoSmithKline PLC
  • Intercept Pharmaceuticals Inc.
  • MediGene AG
  • NGM Biopharmaceuticals Inc.
  • Novartis AG
  • Retrophin Inc.
  • Shire PLC

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/zlh4gw/primary_biliary?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190227005554/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Liver and Kidney Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 02/27/2019 09:43 AM/DISC: 02/27/2019 09:43 AM

http://www.businesswire.com/news/home/20190227005554/en